# A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

Study · id `cardio:ct-nct05443594` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05443594](<https://clinicaltrials.gov/study/NCT05443594>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05443594

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 669 participants.

## Technical summary

Registry record NCT05443594. Non-randomized; no masking; primary purpose treatment. Start 2023-02-28 (actual); primary completion 2025-02-11 (actual). Results posted on 2025-10-24.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 669 participants (enrolled count; ClinicalTrials.gov record NCT05443594, source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)
- Started: 2023-02-28 (actual) (ClinicalTrials.gov record NCT05443594, source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)
- Primary completion: 2025-02-11 (actual) (ClinicalTrials.gov record NCT05443594, source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)
- Completion: 2025-02-11 (actual) (ClinicalTrials.gov record NCT05443594, source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)
- Results first posted: 2025-10-24 (ClinicalTrials.gov record NCT05443594, source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; Spain (ClinicalTrials.gov record NCT05443594, source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05443594-2025-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
- Acronym: ADVANTAGE AF
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): Phase 1: FARAPULSE Ablation System
- Intervention (Device): Phase 2: FARAPULSE Ablation System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2 (`cardio:pubmed-40273320`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy (`cardio:pubmed-41653174`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3045de27edbb9d61a4756391ba415c9a0363dfc6d78f0ca0238f2a55ac688285
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
